Key result
C-type natriuretic peptide increases saphenous vein cGMP ~16-fold over basal levels, surpassing ANP.
Why the study?
The comparative response of intracellular cyclic GMP to C-type natriuretic peptide and atrial natriuretic peptide in human arteries, veins, and cultured vascular smooth muscle cells needed to be determined.
Does C-type natriuretic peptide elicit a different cyclic GMP response compared to atrial natriuretic peptide in human artery and vein smooth muscle cells?
Does C-type natriuretic peptide elicit a different cyclic GMP response compared to atrial natriuretic peptide in human artery and vein smooth muscle cells?
Human smooth muscle cells in arteries and veins express both natriuretic peptide receptors, but atrial natriuretic peptide acts primarily on arteries while C-type natriuretic peptide acts predominantly on veins.
Answers are grounded in this paper and cite their sources.
Differential ANP/CNP cGMP responses in human vessels suggest vessel-specific signaling; leaves open targeted modulation pending in vivo studies.
Objectives We determined the response of intracellular cyclic GMP in human arteries and veins and in smooth muscle cells cultured from these vessels to C-type natriuretic peptide in comparison with atrial natriuretic peptide. Design Repeated-measures analysis of concentration-response curves. Setting Anesthesia research laboratory. Subjects Vascular smooth muscle cells from human blood vessels obtained with Institutional Review Board approval and patient consent. Measurements and main results Segments of internal mammary artery and saphenous vein were obtained from patients undergoing coronary artery bypass surgery. Smooth muscle cells were cultured from these vessels. Concentration-response curves of intracellular cyclic GMP were determined and analyzed by two-way analysis of variance with repeated measures. In segments of intact saphenous vein, C-type natriuretic peptide was significantly more effective than atrial natriuretic peptide (16-fold increase in cyclic GMP in response to 1 microM of C-type natriuretic peptide vs. six-fold increase in cyclic GMP in response to 1 microM of atrial natriuretic peptide, p < .05). In rings of intact internal mammary artery, 1 microM of atrial natriuretic peptide (26-fold increase in cyclic GMP over basal value) was more effective than 1 microM of c-type natriuretic peptide (three-fold increase in cyclic GMP over basal value, p < .05). In cultured cells from these vessels, the pattern of response to C-type natriuretic peptide and atrial natriuretic peptide was the same as in the intact vessels. Conclusions These results indicated that human smooth muscle cells in arteries and veins express both forms of natriuretic peptide receptors but that atrial natriuretic peptide acts primarily on the artery and C-type natriuretic peptide acts predominantly on the vein. Increased concentrations of C-type natriuretic peptide could contribute to venous pooling in septic shock.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (1996) studied Coronary artery bypass surgery. C-type natriuretic peptide vs. Atrial natriuretic peptide (1 microM) was evaluated on Intracellular cyclic GMP response (fold increase over basal value) (p=< .05). C-type natriuretic peptide increased cGMP more than ANP in saphenous vein, whereas ANP was more effective in internal mammary artery.
Synapse has enriched 10 related papers. Consider them for comparative context: